MONARCH 3: Abemaciclib as initial therapy for patients with HR+, HER2-advanced breast cancer - Results from the preplanned final PFS analysis

被引：1
|
作者：
Goetz, Matthew P. [1 ]
Martin, Miguel [2 ,3 ]
Di Leo, Angelo [4 ]
Im, Seock-Ah [5 ]
Awada, Ahmad [6 ]
Forrester, Tammy [7 ]
Frenzel, Martin [7 ]
Cox, Joanne [8 ]
Barriga, Susana [9 ]
Toi, Masakazu [10 ]
Iwata, Hiroji [11 ]
Johnston, Stephen [12 ]
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Geicam, Inst Invest Sanitaria Gregorio Maranon, Ciberonc, Madrid, Spain
[3] Univ Complutense, Madrid, Spain
[4] Hosp Prato, Prato, Italy
[5] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Seoul, South Korea
[6] Jules Bordet Inst, Brussels, Belgium
[7] Eli Lilly & Co, Indianapolis, IN 46285 USA
[8] Eli Lilly & Co, Windlesham, Surrey, England
[9] Eli Lilly & Co, Madrid, Spain
[10] Kyoto Univ, Kyoto, Japan
[11] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[12] Royal Marsden NHS Fdn Trust, London, England
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-CT040
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT040
引用
收藏
页数：2
相关论文
共 50 条
  • [41] MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2--Advanced Breast Cancer
    Neven, Patrick
    Johnston, Stephen R. D.
    Toi, Masakazu
    Sohn, Joohyuk
    Inoue, Kenichi
    Pivot, Xavier
    Burdaeva, Olga
    Okera, Meena
    Masuda, Norikazu
    Kaufman, Peter A.
    Koh, Han
    Grischke, Eva-Maria
    Conte, PierFranco
    Lu, Yi
    Haddad, Nadine
    Hurt, Karla C.
    Llombart-Cussac, Antonio
    Sledge, George W.
    CLINICAL CANCER RESEARCH, 2021, 27 (21) : 5801 - 5809
  • [42] BUDGET IMPACT ANALYSIS OF PALBOCICLIB FOR THE TREATMENT OF PATIENTS WITH HR+/HER2-ADVANCED/METASTATIC BREAST CANCER IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Velchev, M.
    Vekov, T.
    VALUE IN HEALTH, 2018, 21 : S22 - S22
  • [43] A randomized trial of abemaciclib in combination with fulvestrant compared to chemotherapy in women with HR+, HER2-advanced breast cancer with visceral metastases
    Kaufman, Peter
    Glaspy, John
    Zhang, Wei
    Koustenis, Andrew
    Chen, Yanyun
    Brufsky, Adam
    CANCER RESEARCH, 2020, 80 (04)
  • [44] Palbociclib versus abemaciclib in HR+/HER2-advanced breast cancer: an indirect comparison of patient-reported end points
    Law, Ernest
    Gavanji, Roya
    Walsh, Sarah
    Haltner, Anja
    McTavish, Rebecca
    Cameron, Chris
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 11 (02) : 109 - 120
  • [45] Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review
    Wang, Wei
    Wu, Jiayi
    Chen, Keyu
    Wang, Xiaojia
    Shao, Xiying
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [46] PATIENT REPORTED HEALTH UTILITY IN HR+/HER2-ADVANCED/METASTATIC BREAST CANCER
    Mitra, D.
    Wood, R.
    De Courcy, J.
    Iyer, S.
    VALUE IN HEALTH, 2016, 19 (07) : A749 - A749
  • [47] Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review
    Wang, Wei
    Wu, Jiayi
    Chen, Keyu
    Wang, Xiaojia
    Shao, Xiying
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [48] Patterns and outcomes in HR+/HER2-advanced/metastatic breast cancer patients in Brazil receiving palbociclib
    Simon, Patricia
    Jain, Ankita
    Guarin, Alexandra
    Piton, Luciana
    Carvalho, Carla Fabrine
    Lima, Julia
    Nazareth, Felipe
    FUTURE ONCOLOGY, 2024,
  • [49] The prognostic impact of BMI in patients with HR+/HER2-advanced breast cancer: a study of the SONABRE registry
    Lammers, Senna W. M.
    Thurisch, Hannah
    Vriens, Ingeborg J. H.
    Meegdes, Marissa
    Engelen, Sanne M. E.
    Erdkamp, Frans L. G.
    Dercksen, M. Wouter
    Vriens, Birgit E. P. J.
    Aaldering, Kirsten N. A.
    Pepels, Manon J. A. E.
    van de Winkel, Linda M. H.
    Peters, Natascha A. J. B.
    Tol, Jolien
    Heijns, Joan B.
    van de Wouw, Agnes J.
    Teeuwen, Nathalie J. A.
    Geurts, Sandra M. E.
    Tjan-Heijnen, Vivianne C. G.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 203 (02) : 339 - 349
  • [50] COST-EFFECTIVENESS ANALYSIS OF PALBOCICLIB FOR THE TREATMENT OF PATIENTS WITH HR+/HER2-ADVANCED/METASTATIC BREAST CANCER IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Mitova, R.
    Velchev, M.
    Vekov, T.
    VALUE IN HEALTH, 2018, 21 : S31 - S31
12345